<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204164</url>
  </required_header>
  <id_info>
    <org_study_id>TG02-101</org_study_id>
    <nct_id>NCT01204164</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies</brief_title>
  <acronym>TG02-101</acronym>
  <official_title>Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tragara Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tragara Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose escalation Phase 1 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, dose escalation, Phase 1/1b study.&#xD;
&#xD;
      For Parts 1, 2, and 3 of the study, the primary objective is to determine the highest dose of&#xD;
      TG02 citrate that can safely be given to patients with different types of hematological&#xD;
      malignancy.&#xD;
&#xD;
      For Part 4, the primary objective is to evaluate the safety and tolerability of once-weekly&#xD;
      dosing at the maximum-tolerated dose/ Recommended Phase 2 Dose of TG02 in combination with&#xD;
      carfilzomib.&#xD;
&#xD;
      This study consists of four parts:&#xD;
&#xD;
        -  Part 1: single agent TG02 in acute leukemia patients&#xD;
&#xD;
        -  Part 2: single agent TG02 in multiple myeloma patients&#xD;
&#xD;
        -  Part 3: TG02 in combination with carfilzomib in multiple myeloma patients&#xD;
&#xD;
        -  Part 4: TG02 in combination with carfilzomib in carfilzomib refractory multiple myeloma&#xD;
           patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum Tolerated Dose refers to the highest dose of TG02 administered that will produce the desired effect without unacceptable toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>28 days</time_frame>
    <description>Safety data will include vital signs, ECGs, PE findings, clinical laboratory parameters, ECOG PS, AEs/SAEs and concomitant medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TG02</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma will be analyzed to determine TG02 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Response</measure>
    <time_frame>28 days</time_frame>
    <description>Clinical Benefit Response is defined as the sum of all response categories for Overall Response Rate (ORR is defined as the sum of patients with sCR, CR, VGPR and PR) plus minimal response (MR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Overall Response Rate is defined as the sum of patients with sCR, CR, VGPR and PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>28 days</time_frame>
    <description>Progression-Free Survival is the time to disease progression or death, which is measured from the date of first study drug administration until the first date that recurrent or progressive disease is objectively documented or the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>28 days</time_frame>
    <description>Overall Survival is time to death, which is measured from the date of first study drug administration until the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>28 days</time_frame>
    <description>Duration of Response is the duration from first observation of response to the first documentation of disease progression, with deaths from causes other than disease progression censored. For the purposes of the calculation of the DOR, the date at which the response status was first observed rather than the date of confirmation is used as the start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacodynamic sampling may include whole blood and bone marrow at baseline and post-treatment for pathway determination if available.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>Blast Crisis</condition>
  <condition>MDS</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>TG02 in AL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent TG02 citrate in acute leukemia patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TG02 in MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Agent TG02 citrate in multiple myeloma patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TG02 + CFZ in MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TG02 + CFZ + DEX in CFZ refractory MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG02 citrate</intervention_name>
    <description>TG02 citrate capsules given orally.</description>
    <arm_group_label>TG02 + CFZ + DEX in CFZ refractory MM</arm_group_label>
    <arm_group_label>TG02 + CFZ in MM</arm_group_label>
    <arm_group_label>TG02 in AL</arm_group_label>
    <arm_group_label>TG02 in MM</arm_group_label>
    <other_name>No other names.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib per PI</description>
    <arm_group_label>TG02 + CFZ + DEX in CFZ refractory MM</arm_group_label>
    <arm_group_label>TG02 + CFZ in MM</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone (Oral or IV)</description>
    <arm_group_label>TG02 + CFZ + DEX in CFZ refractory MM</arm_group_label>
    <other_name>Ozurdex, Maxidex, Decadron, Baycadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1 Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed AML, ALL, CML in blast crisis, or MDS&#xD;
&#xD;
          -  65+ yrs with AML not eligible for standard frontline chemo&#xD;
&#xD;
          -  Interval from prior treatment to time of study drug at least 5 half-lives for&#xD;
             cytotoxic/ noncytotoxic agents.&#xD;
&#xD;
          -  Persistent clinically significant toxicities from prior chemo ≤ Grd 1&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Lab values:&#xD;
&#xD;
               -  Cr ≤ 2X ULN&#xD;
&#xD;
               -  ALT and/or AST ≤2.5 X ULN&#xD;
&#xD;
               -  Total bilirubin ≤1.5 X ULN unless considered due to Gilbert's syndrome&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Can take oral med&#xD;
&#xD;
        Part 2 Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed multiple myeloma. At least ≥1 line of therapy and progressed after ≥1 prior&#xD;
             therapy&#xD;
&#xD;
          -  Measurable disease defined as at least one of the following:&#xD;
&#xD;
               -  Serum M ≥500 mg/dL&#xD;
&#xD;
               -  Urine M ≥200 mg per 24hr&#xD;
&#xD;
               -  Involved FLC ≥10 mg/dL and abnormal FLC ratio in serum (&lt;0.26 or &gt;1.65)&#xD;
&#xD;
               -  Measurable soft tissue plasmacytoma&#xD;
&#xD;
          -  Persistent clinically significant toxicities from prior chemo ≤ Grd 1&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Lab values:&#xD;
&#xD;
               -  ANC of &gt;1000/mm3&#xD;
&#xD;
               -  Platelets ≥50,000/mm3&#xD;
&#xD;
               -  Cr ≤2X the ULN&#xD;
&#xD;
               -  ALT and/or AST ≤2.5X ULN&#xD;
&#xD;
               -  Total bilirubin ≤1.5X ULN, unless considered due to Gilbert's syndrome&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Can take oral med&#xD;
&#xD;
        Part 3 Inclusion Criteria:&#xD;
&#xD;
          -  Measurable disease defined as at least one of the following:&#xD;
&#xD;
               -  Serum M ≥500 mg/dL&#xD;
&#xD;
               -  Urine M protein ≥200 mg per 24hr&#xD;
&#xD;
               -  Involved FLC level ≥10 mg/dL and abnormal FLC ratio in serum (&lt;0.26 or &gt;1.65)&#xD;
&#xD;
          -  Meet at least one of the criteria below:&#xD;
&#xD;
               -  a. ≥2 prior therapies including proteasome inhibitor and immunomodulatory agent&#xD;
                  (IMiD)&#xD;
&#xD;
               -  b. ≥1 prior therapy and one of the following abnormalities: 17p del, p53, 1q amp,&#xD;
                  1p del, t(4;14)&#xD;
&#xD;
          -  Interval from prior treatment to time of study drug at least 5 half-lives or 3 wks,&#xD;
             which ever is shorter, for noncytotoxic agents&#xD;
&#xD;
          -  Persistent clinically significant toxicities from prior chemo ≤ Grd 1 or Grd 2&#xD;
             neuropathy without pain&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Lab values:&#xD;
&#xD;
               -  ANC of &gt;1000/mm3 independent of G-CSF&#xD;
&#xD;
               -  Platelets ≥50,000/mm3 independent of transfusion&#xD;
&#xD;
               -  MDRD calculated or measured CrCl of ≥30 mL/min&#xD;
&#xD;
               -  ALT and/or AST ≤3X ULN&#xD;
&#xD;
               -  Total bilirubin ≤2X ULN, unless considered due to Gilbert's syndrome&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Can take oral med&#xD;
&#xD;
        Part 4 Inclusion Criteria:&#xD;
&#xD;
          -  Measurable disease defined as at least one of the following:&#xD;
&#xD;
               -  Serum M ≥500 mg/dL&#xD;
&#xD;
               -  Urine M protein ≥200 mg per 24hr&#xD;
&#xD;
               -  Involved FLC level ≥10 mg/dL and an abnormal FLC ratio in serum (&lt;0.26 or &gt;1.65)&#xD;
&#xD;
          -  Received prior therapies including:&#xD;
&#xD;
               -  a. bortezomib&#xD;
&#xD;
               -  b. an IMiD&#xD;
&#xD;
               -  c. carfilzomib. Demonstrated disease progression on or within 60d of completion&#xD;
                  of carfilzomib therapy&#xD;
&#xD;
          -  Interval from prior treatment to time of study drug at least 5 half-lives or 3 wks,&#xD;
             which ever is shorter, for noncytotoxic agents.&#xD;
&#xD;
          -  Persistent clinically significant toxicities from prior chemo ≤ Grd 1, or Grd 2&#xD;
             neuropathy without pain.&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Lab values:&#xD;
&#xD;
               -  ANC of &gt;1000/mm3 independent of G-CSF&#xD;
&#xD;
               -  Platelets ≥50,000/mm3 independent of transfusion&#xD;
&#xD;
               -  MDRD calculated or measured CrCl of ≥30 mL/min&#xD;
&#xD;
               -  ALT and/or AST ≤3X ULN&#xD;
&#xD;
               -  Total bilirubin ≤2X ULN, unless considered due to Gilbert's syndrome&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Can take oral med&#xD;
&#xD;
        Parts 1 and 2 Exclusion Criteria:&#xD;
&#xD;
          -  Previous allogenic hematopoietic transplant within 90 d&#xD;
&#xD;
          -  Concurrent severe or uncontrolled medical disease that would compromise the safety or&#xD;
             compromise the ability of the patient to complete the study&#xD;
&#xD;
          -  Prolonged QTC interval &gt;450ms&#xD;
&#xD;
          -  Symptomatic CNS metastases&#xD;
&#xD;
          -  Known HIV or AIDS&#xD;
&#xD;
          -  Actively treated for a second malignancy&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
        Part 3 Exclusion Criteria:&#xD;
&#xD;
          -  Multiple myeloma of IgM subtype, POEMS, plasma cell leukemia&#xD;
&#xD;
          -  Corticosteroids discontinued ≥7 days of initiating therapy&#xD;
&#xD;
          -  Previous chemo within 2 wks&#xD;
&#xD;
          -  Hx of ventricular arrhythmia or symptomatic conduction abnormality within 12m&#xD;
&#xD;
          -  CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional&#xD;
             intervention, myocardial infarction within 6m&#xD;
&#xD;
          -  Prolonged QTc interval (males &gt;450ms, females &gt;470ms)&#xD;
&#xD;
          -  Previous allogeneic hematopoietic transplant within 90 days of study enrollment,&#xD;
             Active GVHD requiring treatment.&#xD;
&#xD;
          -  Concurrent severe or uncontrolled medical disease that would compromise the safety or&#xD;
             compromise the ability of the patient to complete the study&#xD;
&#xD;
          -  Symptomatic CNS metastases&#xD;
&#xD;
          -  Known HIV or AIDS&#xD;
&#xD;
          -  Prior or 2nd malignancy, except non-melanoma skin cancer, completely resected cervical&#xD;
             or prostate cancer (with PSA of less than or equal to 0.1 ng/ml), or other cancer for&#xD;
             which the subject has received curative therapy at least 3 yrs prior to study entry&#xD;
&#xD;
          -  Treatment-related MDS&#xD;
&#xD;
          -  Significant neuropathy (Grd 3-4 or Grd 2 with pain) at the time of 1st dose&#xD;
&#xD;
          -  Primary AL amyloidosis&#xD;
&#xD;
          -  Pleural effusions requiring thoracentesis or ascites requiring paracentesis&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
        Part 4 Exclusion Criteria:&#xD;
&#xD;
          -  Multiple myeloma of IgM subtype, POEMS, plasma cell leukemia&#xD;
&#xD;
          -  Previous chemo within 2 wks&#xD;
&#xD;
          -  Hx ventricular arrhythmia or symptomatic conduction abnormality within 12m&#xD;
&#xD;
          -  CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional&#xD;
             intervention, and myocardial infarction within 6m&#xD;
&#xD;
          -  Prolonged QTc interval (males &gt;450ms, females &gt;470ms)&#xD;
&#xD;
          -  Previous allogeneic hematopoietic transplant within 90 days. Active GVHD requiring&#xD;
             treatment&#xD;
&#xD;
          -  Concurrent severe or uncontrolled medical disease that would compromise the safety or&#xD;
             compromise the ability of the patient to complete study&#xD;
&#xD;
          -  Symptomatic CNS metastases&#xD;
&#xD;
          -  Known HIV or AIDS&#xD;
&#xD;
          -  Prior or 2nd malignancy, except non-melanoma skin cancer, completely resected cervical&#xD;
             or prostate cancer (with PSA of less than or equal to 0.1 ng/ml), or other cancer for&#xD;
             which the subject has received curative therapy at least 3 yrs prior to study entry&#xD;
&#xD;
          -  Treatment-related MDS&#xD;
&#xD;
          -  Significant neuropathy (Grd 3-4 or Grd 2 with pain) at the time of 1st dose&#xD;
&#xD;
          -  Primary AL amyloidosis&#xD;
&#xD;
          -  Pleural effusions requiring thoracentesis or ascites requiring paracentesis&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T Parrott</last_name>
    <role>Study Director</role>
    <affiliation>Tragara Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RMCC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MDACC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <keyword>CML in blast crisis</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Carfilzomib refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

